Analysts at UBS lower price target on the firm which makes medical devices to A$240 from A$260
** Brokerage downgrades rating on stock to "Sell" from "neutral"
** UBS expects Cochlear's implant sales to be possibly impacted if Moderna MRNA.O makes a vaccine against cytomegalovirus (CMV) infection
** Stock hits lowest since Jan.24
** Three of 16 analysts rate the stock "Buy", seven "Hold" and six "sell" or lower; their median PT is A$260.88 – LSEG data
** Stock has risen 3.3% this year, as of last close
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$317.00 |
Change
4.170(1.33%) |
Mkt cap ! $20.73B | |||
| Open | High | Low | Value | Volume |
| $314.28 | $318.91 | $313.71 | $43.40M | 137.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 324 | $317.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $317.18 | 55 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| COH (ASX) Chart |